



26 June 2018

ASX Announcement / Media Release

Bisantrene poster presented at French Leukaemia Conference

HIGHLIGHTS

- Bisantrene poster presented at the International Conference on Leukaemia and Hematologic Oncology in Paris
- Bisantrene is: “particularly appropriate for the treatment of paediatric r/r AML”

Tuesday 26 June, 2018: Race Oncology Limited (“RAC”) is pleased to announce that a poster on its cancer drug, Bisantrene, was presented at the International Conference on Leukaemia and Hematologic Oncology in Paris on 21 June 2018.

The poster can be viewed at: <https://www.raceoncology.com/investors/>

The poster reports on the long-term follow-up of two French girls with relapsed/refractory AML, who were treated with Bisantrene between 1984 and 1991. Both patients went into remission and remain alive today.

“The Bisantrene poster represents the first time in many years that a new chemotherapy drug for AML has been presented at an international leukaemia conference,” said Race Oncology CEO Peter Molloy.

The poster concludes:

- Bisantrene is therapeutically active, with a unique safety profile that maybe particularly appropriate for the treatment of pediatric r/r AML.
- Published efficacy results from prior salvage studies of bisantrene in adult and pediatric AML and the long-term case reports presented here support a renewed interest in clinical development of bisantrene.



The authors of the poster are Prof. Guy Leverger, a leading French haematology-oncologist from the Armand Trousseau children's hospital in Paris, and Prof. Yves Bertrand, also a leading haematology-oncologist, from the Institute of Paediatric Hemato-Oncology in Lyon.

Both doctors were involved in the original Bisantrene studies in France, which were published in the 1980s and 1990s and contributed to the French marketing approval for Bisantrene.

-ends-

About Bisantrene

Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers, but has been shown to have greatly reduced cardiac toxicity. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. Race owns two patents on the drug, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML, which confers seven years of market exclusivity in US from date of FDA approval.

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of big pharma mergers.

Media contact:

Heidi Cuthbert

+61 411 272 366

E: heidi.cuthbert@multiplier.com.au